Imagine being able to see exactly how a cancer tumor reacts to radiation while the treatment is actually happening, rather than waiting until the end. This technology acts like a high-tech sensor that catches special light signals emitted by the cancer during therapy. It allows doctors to adjust the treatment daily to fit the patient's specific needs without adding extra radiation dose.
Current particle radiation therapy for bone cancer lacks real-time monitoring, forcing doctors to image tumors only at the start and end of treatment. This makes it nearly impossible to personalize doses daily based on the tumor's actual response.
A Technical Design Report for detectors and electronics, a Conceptual Design for the DAQ system, and initial beam test results.
If you are a manufacturer dealing with the lack of real-time feedback in particle therapy — this project developed a specialized detection and collimation system that enables daily monitoring of treatment efficacy. This allows for the creation of a new class of 'smart' radiotherapy machines.
If you are a software provider dealing with the need for high-performance data processing in oncology — this project developed turnkey software for high performance medical devices. This enables the translation of complex spectroscopic data into actionable clinical decisions.
If you are a clinic dealing with the difficulty of personalizing incurable metastatic bone cancer treatment — this project developed a method to separate cancer signals from healthy tissue. This could improve patient quality of life and reduce healthcare system costs.
Based on available project data, there is no specific pricing or cost information provided.
The project anticipates that within 10 years, the technology will benefit all patients treated with proton and carbon ions as the number of PRT centers grows.
Based on available project data, specific patent or licensing details are not mentioned, though the project involves 2 SMEs and 3 research entities.
It integrates by detecting prompt gamma emissions during the standard particle radiation therapy process, removing the need for additional imaging doses.
The project period is from 2025-01-01 to 2029-12-31.
The consortium is well-balanced for a deep-tech medical project, consisting of 6 partners across 5 countries. It maintains a 33% industry ratio with 2 SMEs, ensuring that the research from 3 research institutes and 1 university is grounded in commercial viability, specifically in software and electronics engineering.
Contact the Deutsches Krebsforschungszentrum Heidelberg
Contact us to explore licensing opportunities for real-time spectroscopic bone analysis.
